Mycoplasma gallisepticum Vaccine in Poultry: Protocols and Efficacy

Introduction

Mycoplasma gallisepticum is a wall‑less bacterium belonging to the class Mollicutes and is the primary etiological agent of chronic respiratory disease (CRD) in chickens and infectious sinusitis in turkeys [1]. Infection with M. gallisepticum results in substantial economic losses in commercial poultry operations due to reduced egg production, increased feed conversion ratios, carcass condemnations, and mortality secondary to respiratory complications [1, 2]. The pathogen is transmitted both vertically (transovarian) and horizontally via aerosol, contaminated fomites, and direct bird‑to‑bird contact [1, 2]. Control of M. gallisepticum has historically relied on eradication through serological monitoring and depopulation of infected flocks, but the high density and vertical integration of modern poultry production have made eradication impractical in many regions [1]. Consequently, vaccination has become a key component of integrated control programs [1, 2]. This article provides a detailed examination of available [poultry mycoplasma vaccine] types, their protocols, efficacy data, and the role of vaccination within broader control strategies.

Live Attenuated Vaccines

Live attenuated vaccines against M. gallisepticum are the most widely used category in commercial layers and breeders. Three main strains have been developed and licensed in various countries: the F strain, the ts‑11 strain, and the 6/85 strain [1, 2]. These vaccines are administered via eye drop, spray, or drinking water, depending on the product and target population [1, 2].

F Strain Vaccine

The F strain is a relatively virulent live vaccine derived from a field isolate and is commonly used in multi‑age layer complexes where the pathogen is already endemic [1]. The F strain colonizes the upper respiratory tract and induces a strong local and humoral immune response [1, 2]. However, it retains residual pathogenicity and can cause overt disease in susceptible turkeys and in chickens under stress [1]. For this reason, its use is generally restricted to layer flocks that are already infected or at high risk of exposure [1, 2]. The F strain is typically administered by coarse spray or drinking water to pullets at 8–12 weeks of age, often in combination with the live Mycoplasma synoviae vaccine [1, 2]. Protective immunity develops within 2–3 weeks and persists for the laying period, though booster applications are sometimes employed in long‑production cycles [1].

ts‑11 Strain Vaccine

The ts‑11 strain is a temperature‑sensitive mutant that replicates effectively in the upper respiratory tract at the lower body temperature of the nasal passages but is restricted at core body temperature [1, 2]. This attenuation reduces the risk of systemic spread and clinical disease [1]. The ts‑11 vaccine is administered by eye drop or fine spray, typically as a single dose at 6–10 weeks of age [1, 2]. Studies have demonstrated that ts‑11 protects against challenge with virulent M. gallisepticum without causing significant respiratory signs or egg production losses [2]. It is considered safer than the F strain for use in M. gallisepticum‑naive flocks and is also licensed for use in turkeys in some jurisdictions [1, 2]. Serological differentiation between vaccinated and naturally infected birds can be challenging with conventional serological tests, but molecular typing methods (e.g., gene‑targeted PCR and sequencing) can distinguish vaccine strains from field isolates [1, 2].

6/85 Strain Vaccine

The 6/85 strain is a highly attenuated live vaccine developed from a field isolate after multiple passages in culture [1]. It is administered by coarse spray, typically at 10–14 weeks of age, and provides good protection against respiratory disease and egg production drops [1, 2]. The 6/85 strain is less immunogenic than the F strain but causes minimal adverse reactions and is safe for use in flocks that are not yet infected [1, 2]. It has become a preferred option for layer pullet vaccination programs in several regions [1, 2].

Inactivated Vaccines

Inactivated (killed) vaccines against M. gallisepticum are formulated as bacterins, often adjuvanted with oil emulsions to enhance the immune response [1]. These vaccines are administered via subcutaneous or intramuscular injection, usually at 10–16 weeks of age, with a single dose followed by a booster 3–6 weeks later in some protocols [1, 2]. Inactivated vaccines have the advantage of safety: they cannot revert to virulence or cause disease in vaccinated birds [1]. However, they typically induce a weaker mucosal immune response than live vaccines, which may be less effective at preventing colonization and transmission of field strains [1, 2]. They are often used in breeder flocks to protect against egg transmission and to provide passive immunity to progeny via maternal antibodies [1]. Inactivated vaccines are also employed in layer flocks where live vaccines are contraindicated, such as in multi‑age complexes with high health status [1, 2].

Vaccination Schedules

The optimal vaccination schedule depends on the vaccine type, the production system, and the epidemiological status of the flock [1]. Table 1 summarizes common protocols for live and inactivated M. gallisepticum vaccines.

Table 1. Typical vaccination schedules for Mycoplasma gallisepticum vaccines in commercial layers and breeders.

Vaccination timing is critical to avoid interference with maternal antibodies [1]. In broiler breeders, vaccination is often performed at 8–12 weeks after maternal antibody titers have waned [1, 2]. Layers are typically vaccinated at 8–14 weeks, prior to the onset of egg production, to minimize stress and optimize immune response [1, 2]. Concurrent vaccination with other respiratory vaccines (e.g., Newcastle disease, infectious bronchitis) should be carefully timed to avoid immune interference and adverse reactions [1].

Efficacy and Immunological Mechanisms

Efficacy of M. gallisepticum vaccines is measured by reduction in clinical signs, air‑sac lesion scores, egg production losses, and transmission of the pathogen [1, 2]. Live vaccines, particularly the F strain, have been shown to reduce air‑sacculitis and tracheal colonization by 70–90% in controlled challenge studies [1, 2]. The ts‑11 and 6/85 strains offer comparable protection against respiratory disease but may be less effective at preventing colonization and transmission, especially under high‑challenge conditions [1, 2]. Inactivated vaccines provide moderate protection against clinical disease but are less effective at reducing colonization [1]. Field efficacy data indicate that vaccination programs, combined with strict biosecurity, can reduce the prevalence of M. gallisepticum in endemic areas and prolong the productive life of layer flocks [1, 2].

The immune response to M. gallisepticum involves both humoral and cell‑mediated components [1]. Live vaccines stimulate mucosal IgA production and systemic IgG responses, as well as T‑cell‑mediated immunity [1, 2]. Inactivated vaccines primarily induce systemic IgG through the adjuvanted bacterin, with weaker mucosal responses [1]. Protection correlates most strongly with local IgA and T‑cell memory in the respiratory tract [1]. Vaccinated birds that become infected with a field strain typically show milder clinical signs and reduced shedding, contributing to lowered transmission within the flock [1, 2].

Control Strategies Integrating Vaccination

Vaccination against M. gallisepticum is not a standalone measure. It is most effective when deployed within a comprehensive control program that includes biosecurity, monitoring, and sometimes antimicrobial treatment [1, 2]. Key elements of such a program are:

• Biosecurity: Strict all‑in/all‑out management, single‑age sites where possible, rodent and wild bird control, and disinfection protocols to prevent introduction of M. gallisepticum from external sources [1, 3]. (See Biosecurity Protocols, Sanitation, and Disinfection Interventions in Intensive Poultry Production.)
• Serological monitoring: Regular testing using rapid serum agglutination (RSA) tests, enzyme‑linked immunosorbent assays (ELISAs), or hemagglutination inhibition (HI) assays to detect infected flocks and evaluate vaccine response [1, 2]. (See Mycoplasma gallisepticum and Mycoplasma synoviae Infections in Chickens: Laboratory Diagnosis and Control Strategies.)
• Molecular diagnostics: PCR and sequencing to differentiate vaccine strains from field isolates during outbreak investigations [1, 2].
• Antimicrobial therapy: In flocks with active infection, antibiotics such as tylosin, tilmicosin, or tiamulin may be used therapeutically, but their use should be guided by sensitivity testing and residue avoidance [1, 2, 3]. (See Mycoplasma in Poultry: Causes, Clinical Signs in Chicken Poop, and Control Strategies.)
• Multi‑agent immunization: Coadministration with other vaccines (e.g., infectious bronchitis, Newcastle disease) should follow manufacturer recommendations to minimize interference [1, 2]. (See Fowl Pox and Mycoplasma Gallisepticum Vaccine Considerations in Poultry.)

Decision Workflow for Mycoplasma gallisepticum Vaccination

The following diagram illustrates a decision framework for selecting and implementing a M. gallisepticum vaccination program based on flock status and production type.

flowchart TD
    A[Flock health status determination], > B{Is M. gallisepticum present?}
    B, >|Yes, endemic| C[Consider live F strain vaccine<br>in layers; biosecurity reinforcement]
    B, >|No, naive| D{Production type?}
    D, >|Layer| E[Option A: Live ts11 or 6/85 vaccine<br>at 8-14 weeks]
    D, >|Breeder| F[Option B: Inactivated bacterin<br>at 10-12 weeks + booster]
    D, >|Broiler| G[Vaccination not typically recommended;<br>rely on breeder immunity & biosecurity]
    C, > H[Monitor serology & clinical signs post-vaccination]
    E, > H
    F, > H
    H, > I{Post-vaccination protection adequate?}
    I, >|Yes| J[Continue monitoring and biosecurity]
    I, >|No| K[Revise vaccine strain/route or<br>consider antimicrobial therapy]
    J, > L[Long-term control: periodic re-evaluation]
    K, > L

References

[1] Swayne, D.E., Boulianne, M., Logue, C.M., et al. (eds.). Diseases of Poultry. 14th ed. Wiley‑Blackwell. (Standard reference text; no specific publication year.)

[2] Merck Veterinary Manual. Mycoplasmosis in Poultry. Merck & Co., Inc. (Standard online reference.)

[3] World Organisation for Animal Health (WOAH). Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. Chapter on avian mycoplasmosis. (Standard reference.) *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.